person · Reporting owner
Fitzgerald Joseph Michael
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | EVP & Group Pres, Cardiology | July 31, 2026 | August 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date July 31, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) | 64,198 |
Reported balance
After 2026-07-31 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-07-31 · Other · Acquired 64,198 · Balance 64,198 F1: Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock. F2: Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan. |
| Common StockSEC Table I · non-derivative | Direct | 213,907 |
Reported balance
Holding disclosure · report date 2026-07-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 213,907 |
| Common StockSEC Table I · non-derivative | IndirectBy Child | 5,234 |
Reported balance
Holding disclosure · report date 2026-07-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5,234 F3: The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock.
F2: Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.
F3: The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2019 Filed Jan 3, 2019 21:55 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 7,269 | $35.34 | $256,886.46 |
DisclosureSEC source: 0001225208-19-000436 · doc4.xml · nonDerivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,940 Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:55 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 23,157 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-000436 · doc4.xml · nonDerivative · entry 3 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ends on December 31, 2018. Read SEC document |
| November 19, 2018 Filed Jan 3, 2019 21:55 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 3,256 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-000436 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,052 Read SEC document |
| August 13, 2018 Filed Jan 3, 2019 21:55 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 1,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-000436 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,308 Read SEC document |
| March 03, 2018 Filed Mar 6, 2018 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 3,602 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-005418 · doc4.xml · derivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,412 Underlying: Common Stock · 3,602 shares Expires 2022-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant. Read SEC document |
| March 03, 2018 Filed Mar 6, 2018 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,643 | $26.77 | $43,983.11 |
DisclosureSEC source: 0001225208-18-005418 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,763 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| March 03, 2018 Filed Mar 6, 2018 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,602 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-005418 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 21:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 6,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004942 · doc4.xml · derivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,090 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 21:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 2,778 | $27.26 | $75,728.28 |
DisclosureSEC source: 0001225208-18-004942 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,804 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 21:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 6,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004942 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,582 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 24, 2018 Filed Feb 26, 2018 22:42 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 4,778 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004202 · doc4.xml · derivative · entry 7 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,779 Underlying: Common Stock · 4,778 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| February 24, 2018 Filed Feb 26, 2018 22:42 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 2,179 | $27.20 | $59,268.80 |
DisclosureSEC source: 0001225208-18-004202 · doc4.xml · nonDerivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,492 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 24, 2018 Filed Feb 26, 2018 22:42 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004202 · doc4.xml · nonDerivative · entry 3 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 23, 2018 Filed Feb 26, 2018 22:42 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 4,138 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004202 · doc4.xml · derivative · entry 6 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,278 Underlying: Common Stock · 4,138 shares Expires 2020-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document |
| February 23, 2018 Filed Feb 26, 2018 22:42 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,887 | $27.20 | $51,326.40 |
DisclosureSEC source: 0001225208-18-004202 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,893 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 23, 2018 Filed Feb 26, 2018 22:42 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,138 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004202 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 4,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004004 · doc4.xml · derivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,168 Underlying: Common Stock · 4,055 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,850 | $26.48 | $48,988.00 |
DisclosureSEC source: 0001225208-18-004004 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,642 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004004 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:55 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 69,521 | $0.00 Strike: $27.09 | $0.00 |
DisclosureSEC source: 0001225208-18-003386 · doc4.xml · derivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,521 Underlying: Common Stock · 69,521 shares Expires 2028-02-15 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:55 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 23,071 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-003386 · doc4.xml · derivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,071 Underlying: Common Stock · 23,071 shares Expires 2023-02-15 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 21:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 17,582 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-002891 · doc4.xml · derivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,582 Underlying: Common Stock · 17,582 shares Expires 2019-12-31 F4 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2019. F5 · derivative.exercise_date: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2019. F5 · derivative.expiration_date: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2019. F5 · balance_after: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2019. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 21:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 18,872 | $26.18 | $494,068.96 |
DisclosureSEC source: 0001225208-18-002891 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,437 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 21:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 41,384 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-002891 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,309 F1 · shares: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person was based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2017 and was subject to the completion of the concurrent three-year individual service period. On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 07, 2018 Filed Feb 8, 2018 21:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 85,227 | $0.00 Strike: $12.52 | $0.00 |
DisclosureSEC source: 0001225208-18-002314 · doc4.xml · derivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85,227 shares Expires 2018-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase 85,227 shares of common stock vesting in four annual increments beginning on February 12, 2009, the first anniversary of the grant. Read SEC document |
| February 07, 2018 Filed Feb 8, 2018 21:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 85,227 | $26.48 | $2,256,674.60 |
DisclosureSEC source: 0001225208-18-002314 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,925 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · price: Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $26.39 to $26.57, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 07, 2018 Filed Feb 8, 2018 21:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 85,227 | $12.52 | $1,067,042.04 |
DisclosureSEC source: 0001225208-18-002314 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 22:01 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 22,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-000376 · doc4.xml · derivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,513 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. F1 · derivative.exercise_date: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. F1 · derivative.expiration_date: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 22:01 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 7,813 | $24.79 | $193,684.27 |
DisclosureSEC source: 0001225208-18-000376 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,925 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 22:01 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 22,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-000376 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 21:04 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 306,372 | $0.00 Strike: $26.15 | $0.00 |
DisclosureSEC source: 0001225208-17-018209 · doc4.xml · derivative · entry 3 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,372 Underlying: Common Stock · 306,372 shares Expires 2027-12-01 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant. Read SEC document |
| November 30, 2017 Filed Dec 5, 2017 21:04 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 2,891 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-018209 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,225 F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| March 03, 2017 Filed Mar 6, 2017 22:42 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 57,618 | $0.00 Strike: $24.98 | $0.00 |
DisclosureSEC source: 0001225208-17-005645 · doc4.xml · derivative · entry 3 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,618 Underlying: Common Stock · 57,618 shares Expires 2027-03-03 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant. Read SEC document |
| March 03, 2017 Filed Mar 6, 2017 22:42 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 18,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005645 · doc4.xml · derivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,014 Underlying: Common Stock · 18,014 shares Expires 2018-12-31 F3 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · shares: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On March 3, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F4 · derivative.exercise_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On March 3, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F4 · derivative.expiration_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On March 3, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F4 · balance_after: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On March 3, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. Read SEC document |
| March 03, 2017 Filed Mar 6, 2017 22:42 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 18,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005645 · doc4.xml · derivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,014 Underlying: Common Stock · 18,014 shares Expires 2022-03-03 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:30 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 6,089 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005441 · doc4.xml · derivative · entry 5 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,090 Underlying: Common Stock · 6,089 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. F6 · balance_after: Reflects multiple DSU awards with independent vesting schedules. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:30 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 25,943 | $24.55 | $636,900.65 |
DisclosureSEC source: 0001225208-17-005441 · doc4.xml · nonDerivative · entry 3 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,116 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:30 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 6,089 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005441 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:30 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 47,782 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005441 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,970 F1 · shares: On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person was based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2016 and was subject to the completion of the concurrent three-year individual service period. On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 28, 2017 Filed Jan 3, 2019 14:05 UTC Amendment | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 23,157 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-000171 · doc4a.xml · derivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,157 Underlying: Common Stock · 23,157 shares Expires 2018-12-31 F1 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which is to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F2 · derivative.exercise_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which is to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F2 · derivative.expiration_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which is to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F2 · balance_after: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which is to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:46 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 5,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004923 · doc4.xml · derivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,179 Underlying: Common Stock · 5,972 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. F5 · balance_after: Reflects multiple DSU awards with independent vesting schedules. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:46 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 2,007 | $24.81 | $49,793.67 |
DisclosureSEC source: 0001225208-17-004923 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,188 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:46 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 5,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004923 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 4,778 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004738 · doc4.xml · derivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,557 Underlying: Common Stock · 4,778 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,606 | $24.78 | $39,796.68 |
DisclosureSEC source: 0001225208-17-004738 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,223 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004738 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 23, 2017 Filed Feb 24, 2017 21:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 4,138 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004552 · doc4.xml · derivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,416 Underlying: Common Stock · 4,138 shares Expires 2020-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 24, 2017 21:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,391 | $24.48 | $34,051.68 |
DisclosureSEC source: 0001225208-17-004552 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,051 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 23, 2017 Filed Feb 24, 2017 21:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,138 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004552 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2017 Filed Feb 23, 2017 23:40 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 4,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004429 · doc4.xml · derivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,223 Underlying: Common Stock · 4,055 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.